Tyra Biosciences, Inc.
TYRA
Rank in Stocks
#7487
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on... Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Share Price
$22.30
Last synced: 2026-11-09
Market Cap
$1.33B
Change (1 day)
5.44%
Change (1 year)
44.06%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Tyra Biosciences, Inc. (TYRA)
Category
Healthcare
EPS for Tyra Biosciences, Inc. (TYRA)
EPS as of June 2026 TTM: $-2.40
According to Tyra Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-2.40. At the end of 2025 the company had an EPS of $-2.01, a decrease compared to its 2024 EPS of $-1.51.
EPS history for Tyra Biosciences, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.40 | 19.40% |
| 2025 | $-2.01 | 33.11% |
| 2024 | $-1.51 | -6.79% |
| 2023 | $-1.62 | 31.71% |
| 2022 | $-1.23 | 95.24% |
| 2021 | $-0.63 | 186.36% |
| 2020 | $-0.22 | 130.61% |
| 2019 | $-0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -752.50% |
US
|
|
| $-7.07 | 194.58% |
US
|
|
| $-5.29 | 120.42% |
AU
|
|
| $12.88 | -636.67% |
BE
|
|
| $21.56 | -998.33% |
NL
|
Questions about Tyra Biosciences, Inc.'s earnings per share (EPS)
What is Tyra Biosciences, Inc.'s earnings per share (EPS)?
Tyra Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-2.40, as of Jun 2026.
What was Tyra Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tyra Biosciences, Inc.'s earnings per share (EPS) was $-2.01, compared with $-1.51 in 2024.
How has Tyra Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tyra Biosciences, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.22) and lowest in 2025 ($-2.01).
How does Tyra Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Tyra Biosciences, Inc.'s earnings per share (EPS) ($-2.40) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.